In the latest edition of Life Science Leader, Precision’s Andre Pinheiro, Mansi Vithlani, Kyle Sarnataro, and Alex Grosvenor examine the introduction of Anti-TNF Biosimilars in Europe.
In his latest Forbes.com commentary, Precision Health Economics co-founder Tomas Philipson (along with Precision co-author Jason Shafrin) addresses the development of new value frameworks, and how both physicians and patients are at risk.
Precision Medicine Group is proud to announce that precisioneffect has been named one of the top 100 agencies of 2016 by Medical Marketing & Media.
Precision Health Economics’ Darius Lakdawalla speaks with the AP’s Matthew Perrone and offers some guidelines for drug pricing.
Rick Lifsitz and Larry Blandford address market access for novel Alzheimer’s treatments in a new commentary for Journal of Clinical Pathways
Precision for Value’s Dan Renick offers his perspective on GSK’s Breo in The Pink Sheet.
Dan Renick comments on the importance of value demonstration for respiratory disease treatments in The Pink Sheet.
Pharma Industry Firm Moves for More Space
Precision for Value, a company that helps bring pharmaceutical products to market, has found a larger home at One Grand Central Place.
Flemington, N.J., May 19, 2016 – ACT Oncology announced today it has been awarded the Philadelphia Alliance for Capital and Technologies (PACT) 2016 Enterprise Award for Emerging Healthcare companies. The Enterprise Awards, held annually, are the region’s most prestigious business honors for innovative life sciences and technology companies, leaders, and entrepreneurs.
Peter Neumann, Leader in Health Economics and Outcomes Research, Joins Precision Health Economics as Advisor
Los Angeles, May 17, 2016 — Precision Health Economics (PHE), a global leader in health economic research, policy, and analytics, announced today that Peter Neumann, ScD has joined PHE in the role of principal scientific advisor.